Clinical and Epidemiologic Features of Lupus Nephritis

Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition

Volumn , Issue , 2013, Pages 438-454

  Dooley, Mary Anne ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942923047     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1893-5.00035-2     Document Type: Chapter

References (62)

1. Danila MI, Pons-Estel GJ, Zhang J, et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009, 48(5):542-545.
2. Dooley MA Clinical and epidemiologic features of lupus nephritis. Dubois' lupus erythematosus 2007, 1112-1130. Lippincott Williams & Wilkins, Philadelphia. ed 7. D.J. Wallace, B. Hahn, E.L. Dubois (Eds.).
3. Walsh SJ, Algert C, Gregorio DI, et al. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 1995, 22:1663-1668.
4. Pistiner M, Wallace DJ, Nessim S, et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991, 21:55-64.
5. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006, 69:1846-1851.
6. Croca SC, Rodrigues T, Isenberg DA Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011, 50(8):1424-1430.
7. Nossent JC, Bronsveld W, Swaak AJ Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989, 48:810-816.
8. Ward MM Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009, 36:63-67.
9. Wallace DJ, Podell T, Weiner J, et al. Systemic lupus erythematosus-survival patterns. Experience with 609 patients. JAMA 1981, 245:934-938.
10. Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow up of patients with lupus nephritis. A study based on the classification of the world health organization. Am J Med 1987, 83:877-885.
11. Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic variables of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999, 34:530-539.
12. Eiser AR, Katz SM, Swartz C Clinically occult diffuse proliferative lupus nephritis: an age related phenomenon. Arch Intern Med 1979, 139:1022-1025.
13. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250.
14. Hwang J, Kim HJ, Oh JM, et al. Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study. Rheumatol Int 2011, [Epub ahead of print].
15. Baldwin DS, Lowenstein J, Rothfield NF, et al. The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 1970, 73:929-942.
16. Pollak VE, Pirani CL, Schwartz FD The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964, 63:537-550.
17. Appel GB, Silva FG, Pirani CL, et al. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978, 57:371-410.
18. McCluskey R Lupus nephritis 1975, Appleton-Century Crofts, East Norwalk, Conn.
19. Churg J, Sobin L Renal Disease: classification and atlas of glomerular diseases 1982, Igaku-Shoin, New York.
20. Churg J, Bernstein J, Glassock R Renal disease: classification and atlas of glomerular diseases 1995, Igaku-Shoin, New York.
21. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004, 65:521-530.
22. Silva F The nephropathies of systemic lupus erythematosus 1983, Churchill Livingston, New York.
23. Schwartz MM, Lan SP, Bonsib SM, et al. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989, 13:273-283.
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
25. Ward MM, Studenski S Age associated clinical manifestations of systemic lupus erythematosus: a multivariate regression analysis. J Rheumatol 1990, 17:476-481.
26. Maddison P, Farewell V, Isenberg D, et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol 2002, 29:913-917.
27. Cooper GS, Parks CG, Treadwell EL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002, 11:161-167.
28. Bastian HM, Roseman JM, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002, 11:152-160.
29. Adler M, Chambers S, Edwards C, et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 2006, 45:1144-1147.
30. Johnson SR, Urowitz MB, Ibañez D, et al. Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. J Rheumatol. 2006, 33:1990-1995.
31. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343:1156-1162.
32. Petri M Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. Lupus 2005, 14:970-973.
33. Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997, 51:1188-1195.
34. Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008, 3:46-53. Collaborative Study Group.
35. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005, 14:890-895.
36. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010, 49:128-140.
37. Lin CP, Adrianto I, Lessard CJ, et al. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 2012, 13:232-238.
38. Klippel JH Predicting who will get lupus nephritis. J Clin Rheumatol 1995, 1:257-259.
39. Yeung CK, Ng WL, Wong WS, et al. Acute deterioration in renal function in systemic lupus erythematosus. Q J Med 1985, 56:393-402.
40. Balow JE, Austin HA Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 2003, 23:386-391.
41. Steiman AJ, Gladman DD, Ibañez D, et al. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010, 37:1822-1827.
42. Patel SB, Korbet SM, Lewis EJ The prognosis of severe lupus nephritis based on the Modification of Diet in Renal Disease (MDRD) study estimated glomerular filtration rate. Lupus 2011, 20:256-264.
43. Zhang W, Aghdassi E, Reich HN, et al. Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. Rheumatology (Oxford) 2011, 50:799-805.
44. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004, 50:3934-3940.
45. Sessions S, Mehta K, Kovarsky J Quantitation of proteinuria in systemic lupus erythematosus by random, spot urine collection. Arthritis Rheum 1983, 26:918-920.
46. Ardoin S, Birmingham DJ, Hebert PL, et al. An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis. Arthritis Rheum 2011, 63:2031-2037.
47. Herbert LA, Dillon JJ, Middendorf DF, et al. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995, 26:432-438.
48. Liaño F, Mampaso F, Garcia Martin F, et al. Allograft membranous glomerulonephritis and renal vein thrombosis in a patients with a lupus anticoagulant factor. Nephrol Dial Transplant 1988, 3:684-689.
49. Dubois EL Lupus erythematosus: a review of the current status of discoid and systemic lupus erythematosus and their variants 1976, USC Press, Los Angeles. ed 2.
50. Ward MM Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int 2000, 57:2136-2143.
51. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614-619.
52. Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992 Sep 26, 340:741-745.
53. Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996, 125:549-557.
54. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971-980.
55. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121.
56. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010, 69:61-64.
57. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006, 70:732-742. Dutch Working Party on Systemic Lupus Erythematosus.
58. Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007, 56:924-937. Dutch Working Party on Systemic Lupus Erythematosus.
59. Arends S, Grootscholten C, Derksen RH, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 2011 Nov 29, on behalf of the Dutch Working Party on Systemic Lupus Erythematosus, [Epub ahead of print].
60. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112.
61. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011, 365:1886-1895.
62. Houssiau FA, D'Cruz D, Saugle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the maintain nephritis trial. Ann Rheum Dis 2010, 69:2083-2089.